We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells.
- Authors
Takács, Angéla; Szász, Zsófia; Kalabay, Márton; Bárány, Péter; Csámpai, Antal; Hegyesi, Hargita; Láng, Orsolya; Lajkó, Eszter; Kőhidai, László
- Abstract
Combination antitumor treatments are essential parts of modern tumor therapy as—compared to monotherapies—(i) they are more effective; (ii) the dose of the compounds can be reduced; and (iii) therefore the side effects are improved. Our research group previously demonstrated the antitumor character of bortezomib (BOZ) in A2058 melanoma cells. Unfortunately, dose-related side effects are common during BOZ therapy, which could be prevented by reducing the dose of BOZ. This study aimed to characterize synergistic combinations of BOZ with a TRAIL (TNF-related apoptosis-inducing ligand) -inducing compound (TIC10), where the doses can be cut down but the efficacy is preserved. Endpoint cell viability assays were performed on A2058 cells, and synergism of BOZ and TIC10 was observed after 72 h. Synergism was further validated in a real-time impedimetric assay, and our results showed that BOZ-treated melanoma cells survived the treatment, an effect not registered in the co-treatments. Treatment with the combinations resulted in increased apoptosis, which was not accompanied by enhanced LDH release. Nevertheless, the expression of death receptor 5 (DR5) was increased on the cell surface without transcriptional regulation. In summary, our findings support the theory that the application of BOZ and TIC10 in combination could provide higher efficacy in vitro.
- Subjects
BORTEZOMIB; DEATH receptors; MELANOMA; CELL survival; RESEARCH teams
- Publication
Pharmaceuticals (14248247), 2021, Vol 14, Issue 8, p820
- ISSN
1424-8247
- Publication type
Article
- DOI
10.3390/ph14080820